Open-Label Trial of Recombinant Human Insulin-like Growth Factor 1/Recombinant Human Insulin-like Growth Factor Binding Protein 3 in Myotonic Dystrophy Type 1
Open Access
- 1 January 2011
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 68 (1), 37-44
- https://doi.org/10.1001/archneurol.2010.227
Abstract
Myotonic dystrophy type 1 (DM1) is a progressive multisystem degenerative disorder caused by expansion of a CTG repeat in the dystrophia myotonica protein kinase (DMPK) gene.1 Currently there is no known treatment capable of modifying the progressive myopathy of DM1.Keywords
This publication has 30 references indexed in Scilit:
- Reliability and feasibility of the six minute walk test in subjects with myotonic dystrophyNeuromuscular Disorders, 2007
- Computerized hand grip myometry reliably measures myotonia and muscle strength in myotonic dystrophy (DM1)Muscle & Nerve, 2007
- Quantitative analysis of the “warm‐up” phenomenon in myotonic dystrophy type 1Muscle & Nerve, 2005
- Impact of irritable bowel syndrome on patients?? lives: development and psychometric documentation of a disease-specific measure for use in clinical trialsEuropean Journal of Gastroenterology & Hepatology, 2005
- Pharmacokinetics and bioavailability of rhIGF-I/IGFBP-3 in the rat and monkeyProgress in Growth Factor Research, 1995
- Benefit of systemically administered rhIGF-I and rhIGF-I/IGFBP-3 on cancellous bone in ovariectomized ratsJournal of Bone and Mineral Research, 1994
- ErratumCell, 1992
- Mechanism of muscle wasting in myotonic dystrophyAnnals of Neurology, 1990
- In vivo estimation of muscle protein synthesis in myotonic dystrophyAnnals of Neurology, 1985
- Muscle wasting in muscular dystrophy: Decreased protein synthesis or increased degradation?Annals of Neurology, 1983